Public Employees Retirement Association of Colorado lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,942 shares of the biotechnology company’s stock after purchasing an additional 1,840 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Exelixis were worth $1,640,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in EXEL. Dimensional Fund Advisors LP raised its stake in shares of Exelixis by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 620,096 shares of the biotechnology company’s stock worth $15,273,000 after purchasing an additional 28,195 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in shares of Exelixis during the second quarter worth approximately $3,449,000. California State Teachers Retirement System raised its stake in shares of Exelixis by 14.9% during the second quarter. California State Teachers Retirement System now owns 515,076 shares of the biotechnology company’s stock worth $12,686,000 after purchasing an additional 66,783 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Exelixis by 123.7% during the second quarter. Public Employees Retirement System of Ohio now owns 233,322 shares of the biotechnology company’s stock worth $5,747,000 after purchasing an additional 129,008 shares during the last quarter. Finally, Fisher Asset Management LLC purchased a new stake in shares of Exelixis during the third quarter worth approximately $213,000. Institutional investors and hedge funds own 81.43% of the company’s stock.
Exelixis, Inc. (NASDAQ:EXEL) opened at $29.18 on Friday. Exelixis, Inc. has a twelve month low of $18.03 and a twelve month high of $32.50. The firm has a market capitalization of $8,810.51, a price-to-earnings ratio of 58.39, a P/E/G ratio of 0.84 and a beta of 1.84.
Several equities research analysts have recently commented on EXEL shares. Oppenheimer restated a “hold” rating on shares of Exelixis in a research note on Tuesday, December 19th. SunTrust Banks restated a “buy” rating and set a $38.00 price target on shares of Exelixis in a research note on Thursday, December 21st. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective on the stock in a report on Tuesday, January 2nd. Cann reaffirmed a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Finally, BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Exelixis has a consensus rating of “Buy” and an average price target of $32.13.
In related news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Public Employees Retirement Association of Colorado Has $1.64 Million Stake in Exelixis, Inc. (EXEL)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/17/public-employees-retirement-association-of-colorado-has-1-64-million-stake-in-exelixis-inc-exel.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.